gh research is a privately-held clinical-stage biopharmaceutical company developing novel therapies for the management of mental illness.
Company profile
Ticker
GHRS
Exchange
Website
CEO
Theis Terwey
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
GHRS stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
10 Apr 24
6-K
Current report (foreign)
15 Mar 24
20-F
2023 FY
Annual report (foreign)
7 Mar 24
6-K
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
29 Feb 24
6-K
Current report (foreign)
18 Jan 24
6-K
Current report (foreign)
5 Jan 24
6-K
Current report (foreign)
13 Nov 23
6-K
Unaudited condensed consolidated interim statement of comprehensive income
9 Nov 23
6-K
Current report (foreign)
6 Oct 23
6-K
GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression
29 Sep 23
Latest ownership filings
SC 13G
Lynx1 Capital Management LP
16 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
30 Mar 23
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 23
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 23
SC 13G/A
Schonharting Florian
10 Feb 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2023
81.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 36 |
Opened positions | 6 |
Closed positions | 0 |
Increased positions | 8 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 350.94 bn |
Total shares | 42.43 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 9.28 mm | $0.00 |
BVF | 9.28 mm | $110.05 bn |
Ra Capital Management | 5.59 mm | $66.29 bn |
FMR | 4.13 mm | $48.96 bn |
Venrock Healthcare Capital Partners II | 3.52 mm | $0.00 |
VR Adviser | 3.52 mm | $41.73 bn |
RTW Investments | 2.17 mm | $25.73 bn |
Lynx1 Capital Management | 969.37 k | $11.50 bn |
Verition Fund Management | 796.17 k | $9.45 bn |
Orbimed Advisors | 736.32 k | $8.74 bn |
News
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
17 Apr 24
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
29 Mar 24
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
20 Mar 24
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
4 Mar 24
HC Wainwright & Co. Reiterates Buy on GH Research, Maintains $40 Price Target
4 Mar 24